Mini Review ARTICLE
Glioblastoma multiforme: an overview of emerging therapeutic targets
- 1School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Australia
- 2Hunter Medical Research Institute, University of Newcastle, Australia
Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain tumour in humans and has a very poor prognosis. The existing treatments have had limited success in increasing overall survival. Thus, identifying and understanding the key molecule(s) responsible for the malignant phenotype of GBM will yield new potential therapeutic targets. The treatment of brain tumours faces unique challenges, including the presence of the blood brain barrier (BBB), which limits the concentration of drugs that can reach the site of the tumour. Nevertheless, several promising treatments have been shown to cross the BBB and have shown promising pre-clinical results. This review will outline the status of several of these promising targeted therapies.
Keywords: Glioblastoma, anti-cancer drugs, Targeted Therapeutics, brain cancer, Immunotherapy
Received: 23 Jul 2019;
Accepted: 11 Sep 2019.
Copyright: © 2019 Taylor, Brzozowski and Skelding. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Kathryn A. Skelding, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia, Kathryn.Skelding@newcastle.edu.au